Analyst firms · UBS · BHVN

UBS BHVN price target and rating history

Biohaven Ltd. (BHVN) · Health Care

UBS rates Biohaven Ltd. (BHVN) Neutral with a $11 price target, as of its latest action on Nov 26, 2025. It has published 3 rating actions on BHVN since August 2021, including 0 upgrades and 2 downgrades. Across 6 firms with a BHVN price target in the last 12 months, the median target is $15. UBS's $11 is 27% below that.

Current rating

Neutral

Price target

$11

Median target, all firms

$15

Actions on BHVN

3

UBS price target on BHVN

Every UBS rating on BHVN

• Nov 26, 2025
  DowngradeUBS downgrades to Neutral from Buy, price target $11
• Feb 6, 2024
  InitiateUBS starts coverage at Buy, price target $59
• Aug 10, 2021
  DowngradeUBS downgrades to Neutral from Buy, price target $108 to $109

How other firms rate BHVN

Each firm's latest rating and stated target in the last 12 months.

Questions about UBS and BHVN

What is UBS's price target for BHVN?

UBS's latest stated price target for Biohaven Ltd. (BHVN) is $11, from its action on Nov 26, 2025.

What is UBS's rating on BHVN?

UBS rates BHVN Neutral, a neutral rating, as of Nov 26, 2025.

When did UBS last change its view on BHVN?

On Nov 26, 2025, UBS downgrades to Neutral from Buy, price target $11.

How does UBS's BHVN target compare with other analysts?

Across 6 firms with a BHVN price target in the last 12 months, the median target is $15. UBS's $11 is 27% below that.

More BHVN rating histories

• RBC Capital Markets4
• H.C. Wainwright4
• Morgan Stanley4
• Piper Sandler3
• Mizuho4

All UBS ratingsBHVN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.